Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 6/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484456 | 1.00 | P4HB (0.56) | P4HBTHRBHTTLMNASMN1; SMN2 | |
| SCHEMBL3484504 | 0.92 | P4HB (0.57) | P4HBTHRBHTTLMNASMN1; SMN2 | |
| SCHEMBL3484500 | 0.92 | P4HB (0.57) | P4HBTHRBHTTLMNASMN1; SMN2 | |
| SCHEMBL3484188 | 0.92 | LMNA (0.55) | P4HBHTTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL3484185 | 0.92 | LMNA (0.55) | P4HBHTTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL3483949 | 0.89 | P4HB (0.69) | P4HBLMNASMN1; SMN2NPSR1 | |
| SCHEMBL3483951 | 0.89 | P4HB (0.69) | P4HBLMNASMN1; SMN2NPSR1 | |
| SCHEMBL30384818 | 0.89 | P4HB (0.69) | P4HBLMNASMN1; SMN2NPSR1 | |
| SCHEMBL3484321 | 0.89 | XDH (0.54) | P4HBLMNANPSR1 | |
| SCHEMBL3484319 | 0.89 | XDH (0.54) | P4HBLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601943-B1 | Anti-cancer composition containing chalcone compounds | SEOUL NAT UNIV IND FOUNDATION (KR) | 2015-07-22 | — | — | EP | claimed |
| US-20130178533-A1 | COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE | SNU R&DB FOUNDATION (KR) | 2013-07-11 | — | — | US | claimed |
| EP-2601943-A1 | Anti-cancer composition containing chalcone compounds | Seoul National University Industry Foundation (KR) | 2013-06-12 | — | — | EP | claimed |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2010-03-18 | — | — | US | claimed |
| EP-2601943-B1 | Anti-cancer composition containing chalcone compounds | SEOUL NAT UNIV IND FOUNDATION (KR) | 2015-07-22 | — | — | EP | disclosed |
| US-9072698-B2 | Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2015-07-07 | — | — | US | disclosed |
| US-9057725-B2 | Composition for diagnosing, treating, and preventing liver disease | SNU R&DB FOUNDATION (KR) | 2015-06-16 | — | — | US | disclosed |
| US-20130178533-A1 | COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE | SNU R&DB FOUNDATION (KR) | 2013-07-11 | — | — | US | disclosed |
| EP-2601943-A1 | Anti-cancer composition containing chalcone compounds | Seoul National University Industry Foundation (KR) | 2013-06-12 | — | — | EP | disclosed |
| US-8445722-B2 | Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) | 2013-05-21 | — | — | US | disclosed |
| EP-2099440-B1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 | SEOUL NAT UNIV IND FOUNDATION (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120282619-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY | 2012-11-08 | — | — | US | disclosed |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2010-03-18 | — | — | US | disclosed |
| EP-2099440-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | Seoul National University Industry Foundation (KR) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008069608-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | TM9SF4, TM9SF2, TM9SF3 | P4HB 1301/4885THRB 1985/4885HTT 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.